New Valuations

Smith and Nephew's(NYSE:SNN) progress in expanding margins over the year is being tempered by modest growth in revenues. Revenues from Orthopaedic segment is expected to be continue being impacted by pricing pressure while Endoscopy segment revenues are expected to be challenged by capital expenditure constraints implemented by hospitals in view of prevailing economic conditions. We expect the Advanced Wound Management segment to benefit from deeper penetration in Europe as a result of consolidation of the company's UK sales distribution network. The company's new manufacturing unit in China is responsible for production of the ALLEVYN gentle range. We believe cheaper production costs will result in further improvement in margins going forward. New products such as R3 Acetabular System, PROMOS Modular Shoulder System, TRUCLEAR System, ACTICOAT Flex and ALLEVYN products are expected to contribute significantly to revenue growth over the next 2 years. Moreover, Smith and Nephew's acquisition of Nucryst assets on 12 November 2009 bodes well with the company's strategy of investing for growth in each of their businesses by providing them with opportunities in nanocrystalline silver technology, which is expected to benefit the AWM segment. Margins are expected to continue expanding as a result of implementation of EIP, further supported by stricter cost cutting measures and favorable product mix. Consequently, we believe the benefits from the EIP will continue improving EBITDA margin over the next year, despite pressure on revenues due to weak economic conditions. Hence, we maintain our positive outlook for the company.

In 3Q 09 Sprint Sprint Nextel Corporation (NYSE:S)depicted a moderate improvement in prepaid and postpaid gross additions reflecting new competitive innovative plans launched during the quarter and a widening mobile device portfolio. However, despite continues improvement in customer service standards, churn rate has not shown any significant improvement and the increasing Cost of Acquisition (CoA) and subsidy expenses are proving fatal for already deteriorating margins in a highly competitive and maturing market. Nonetheless, we believe that improving customer services, first mover advantage in 4G, an increasing portfolio of new mobile devices and Pan US broadband presence will help improve churn & gross additions and will drive revenues, going forward. At the same time, in line with Management expectations we believe that increasing subsidies in the wake of increasing competition will keep margins and costs under pressure, going forward. As a result we have revised our operating and net losses estimates upwards.

From September 2009, the Research Oracle will begin to accept research submissions from readers – whether amateur or professional analysts – from around the globe. To receive notification of the launch and rules, contributors may register now at
http://www.iirgroup.com/researchoracle/researchoracleaward

Read the full reports free of charge with free to view access to institutional-quality research on 400 companies and over 700 stocks at www.researchoracle.com

Important information for US investors.

With the ending of the Spitzer settlement in July 2009 there will be a dramatic reduction of free independent research available to investors like yourself. Although this will not impact the Research Oracle, we believe that freely available independent research is crucial for a healthy market to function. Ask your broker a/e what plans they expect to implement to continue to provide you with independent research. You may wish to read this recent coverage from TIME Magazine for more information.
Copyright © 2009 Independent International Investment Research PLC. All rights reserved.

http://www.time.com/time/business/article/0,8599,1893519,00.html